Select Bibliography

Filter by any of these (after searching):

DeSchryver, K.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 5 items

Whole-genome analysis informs breast cancer response to aromatase inhibition

Ellis, M. J. , Ding, L. , Shen, D. , Luo, J. Q. , Suman, V. J. ... - - Nature - 2012

Manuscript - Secondary-not-in-original - Comprehensive - PPP - ACOSOG-Z1031

Tumor Ki67 Proliferation Index within 4 Weeks of Initiating Neoadjuvant Endocrine Therapy for Early Identification of Non-Responders

Ellis, M. , Luo, J. , Tao, Y. , Hoog, J. , Snider, J. , DeSchryver, K. ... - SABCS - Cancer Research - 2009

Abstract - Secondary - Primary - Correl Sci NOS - ACOSOG-Z1031

PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy

Liu, M. , Pitcher, B. , Mardis, E. , Davies, S. , Snider, J. ... - AACR - Cancer Res - 2012

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-9741

ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor positive breast cancer

Olson, J. A., Jr , Babiera, G. V. , Unzeitig, G. , Marcom, P. K. ... - ASCO Breast - Breast Cancer Symposium - 2010

Abstract - Primary - Primary - Breast - ACOSOG-Z1031

Validation of the Preoperative Endocrine Prognostic Index in the ACOSOG (Alliance) Z1031 Neoadjuvant Aromatase Inhibitor Trial

Sanati, Souzan , Suman, Vera J. , Goncalves, R. , DeSchryver, K. ... - SABCS - Cancer Res - 2015

Abstract - Secondary - Primary - Breast - ACOSOG-Z1031B